



Topical therapy with negative allosteric modulators of the calcium-sensing receptor (calcilytics) for the management of asthma: the beginning of a new era?

Daniela Riccardi¹, Jeremy P.T. Ward ², Polina L. Yarova³, Luke J. Janssen⁴, Tak Hong Lee^{2,5}, Sun Ying⁶ and Chris J. Corrigan²

¹Cardiff School of Biosciences, University of Cardiff, Cardiff, UK. ²Faculty of Life Sciences and Medicine and Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, London, UK. ³Translational and Clinical Research Institute, School of Medical Sciences, Newcastle University, Newcastle, UK. ⁴Dept of Medicine, McMaster University, Hamilton, ON, Canada. ⁵Hong Kong Sanatorium and Hospital, Hong Kong, China. ⁶Dept of Immunology, School of Basic Medical Sciences, Capital Medical University, Beijing, China.

Corresponding author: Chris J. Corrigan (chris.corrigan@kcl.ac.uk)



Shareable abstract (@ERSpublications)

Negative allosteric modulators of the calcium-sensing receptor (calcilytics) delivered topically to the airways have the potential to revolutionise asthma therapy <https://bit.ly/3tdSZkC>

Cite this article as: Riccardi D, Ward JPT, Yarova PL, *et al.* Topical therapy with negative allosteric modulators of the calcium-sensing receptor (calcilytics) for the management of asthma: the beginning of a new era? *Eur Respir J* 2022; 60: 2102103 [DOI: 10.1183/13993003.02103-2021].

This single-page version can be shared freely online.

Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org

Received: 19 April 2021
Accepted: 16 Dec 2021

Abstract

In this review article we present the evidence to date supporting the role of the calcium-sensing receptor (CaSR) as a key, pluripotential molecular trigger for asthma and speculate on the likely benefits of topical therapy of asthma with negative allosteric modulators of the CaSR: calcilytics.